Pharma News

Heart attacks in women are more likely to be fatal than in men. The reasons are differences in age and in comorbidity burden which makes risk assessment in women a challenge. Researchers at the University of Zurich have now developed a novel artificial-intelligence-based risk score that improves personalized care for female patients with heart attacks.

A study of mice found that dietary sugar alters the gut microbiome, setting off a chain of events that leads to metabolic disease, pre-diabetes, and weight gain.

The findings, published today in Cell(link is external and opens in a new window), suggest that diet matters, but an optimal microbiome is equally important for the prevention of metabolic syndrome, diabetes, and obesity.
Diet alters microbiome.

The Japan health Ministry has approved Evusheld of AstraZeneca for COVID-19. Evusheld is an investigational medicine used in adults and adolescents for pre-exposure prophylaxis for prevention of COVID-19.

In December 2021, the U.S. Food and Drug Administration had approved AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together)for emergency use for prophylaxis of COVID-19. And followed by March 2022, EMA's human medicines committee (CHMP) has recommended granting a marketing authorisation for Evusheld.

​​The US government said yesterday that it would provide about USD 11 million to support the packaging of Jynneos monkeypox vaccine at a U.S. based manufacturers facility, as reported by Reuters.​

Assam based Association of Advanced Pharmacy Practitioners (AAPP) decides that they will not participate in the forthcoming World Pharmacist Day celebration programme on 25th September as a mark of resentment over the issue of not maintaining uniform standard of national eligibility in Pharmacy admission procedure.

A three-drug medication known as a polypill, developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.  These are findings from the SECURE trial led by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC.

Bayer announced the start of a Phase III clinical development program OCEANIC to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor, as a potential new treatment in patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

To commemorate 25 years of existence of National Pharmaceutical Pricing Authority (NPPA), a programme will be organised at the Dr. Ambedkar International Centre, Janpath. Union Minister for Chemicals & Fertilizers and Health & Family Welfare Dr. Mansukh Mandaviya will grace the occasion as Chief Guest. MoS for Chemicals & Fertilizers and New & Renewable Energy will grace the occasion as Guest of Honour.

Novartis said its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to other therapies, as reported by Reuters.

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments.